The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated massive gains, the lapse of its exclusive rights opened the floodgates to off-brand https://bookmarkgenius.com/story21503426/the-copyright-and-big-pharma-a-risky-bet